Published in J Clin Oncol on February 01, 1994
Persistent mobility disability after neurotoxic chemotherapy. Phys Ther (2010) 1.55
Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer (2004) 1.29
A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. Int J Hyperthermia (2010) 1.04
Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study. Br J Cancer (2001) 0.86
A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer. Int J Clin Oncol (2008) 0.85
Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy. Invest New Drugs (1998) 0.83
Neuromuscular toxicities of paclitaxel 210 mg m(-2) by 3-hour infusion. Br J Cancer (1998) 0.81
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer (1996) 0.80
"Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183". Invest New Drugs (2014) 0.79
Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan. BMS-181339 Breast Cancer Study Group. Invest New Drugs (1998) 0.78
Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430. J Thorac Oncol (2008) 0.77
Phase I studies of weekly administration of cytotoxic agents: implications of a mathematical model. Invest New Drugs (2003) 0.77
Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. Invest New Drugs (1997) 0.77
Paclitaxel: what schedule? What dose? J Clin Oncol (1994) 0.77
Taxanes: their impact on gynecologic malignancy. Anticancer Drugs (2014) 0.75
Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study. Br J Cancer (1997) 0.75
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med (2001) 5.59
Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med (1996) 5.46
Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med (2001) 3.98
Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant (2001) 2.10
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood (2001) 2.04
Medical service redesign shares the load saving 6000 bed days and improving morale. Intern Med J (2014) 2.00
Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia (2006) 1.92
Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group. Lancet (1991) 1.82
Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res (1996) 1.77
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood (1997) 1.64
Liver transplantation in children less than 1 year of age. J Pediatr (1990) 1.55
Size reduction of the donor liver is a safe way to alleviate the shortage of size-matched organs in pediatric liver transplantation. Ann Surg (1990) 1.50
Expression of tumor necrosis factor receptors on human monocytes and internalization of receptor bound ligand. J Immunol (1987) 1.49
Prognosis of patients treated with whole-brain radiation therapy for metastatic gestational trophoblastic disease. Gynecol Oncol (1998) 1.42
The concept and technique of the split liver in clinical transplantation. Surgery (1990) 1.41
Utility of medical ethics. Intern Med J (2003) 1.38
Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst (1997) 1.35
Induction of tumor necrosis factor expression and resistance in a human breast tumor cell line. Proc Natl Acad Sci U S A (1987) 1.34
Chronic kidney disease following non-myeloablative hematopoietic cell transplantation. Am J Transplant (2006) 1.29
Direct bypassing of extrahepatic portal venous obstruction in children: a new technique for combined hepatic portal revascularization and treatment of extrahepatic portal hypertension. J Pediatr Surg (1998) 1.27
Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin Cancer Res (1997) 1.27
Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant (2001) 1.25
Effectiveness of smoking cessation interventions integrated into primary care practice. Med Care (1988) 1.23
Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. Cancer Res (1988) 1.22
A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans. J Clin Invest (1990) 1.20
Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J Clin Oncol (1994) 1.18
Staurosporine-induced apoptosis in cardiomyocytes: A potential role of caspase-3. J Mol Cell Cardiol (1998) 1.17
Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly. Cancer Res (1991) 1.16
Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. Int J Cancer (2000) 1.15
Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology (1999) 1.13
Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res (2000) 1.12
Effect of tumor necrosis factor on GTP binding and GTPase activity in HL-60 and L929 cells. J Biol Chem (1988) 1.10
Progressive cardiac failure following orthotopic liver transplantation for type IV glycogenosis. Eur J Pediatr (1992) 1.09
Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant (2000) 1.09
Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J Clin Oncol (2001) 1.08
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol (1997) 1.07
Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group. Nephrol Dial Transplant (1996) 1.07
Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J Natl Cancer Inst (1988) 1.06
Lateralized and widespread brain activation during transient blood pressure elevation revealed by magnetic resonance imaging. J Comp Neurol (2000) 1.05
Regional brain activation in humans during respiratory and blood pressure challenges. Clin Exp Pharmacol Physiol (1998) 1.04
Congenital absence of portal vein with nodular regenerative hyperplasia of the liver. Eur Radiol (2000) 1.03
Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation. Blood (2001) 1.03
Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol (1996) 1.03
Immunomodulatory effects of mixed hematopoietic chimerism: immune tolerance in canine model of lung transplantation. Am J Transplant (2009) 1.02
Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant (2002) 1.01
Cirrhosis of the liver in long-term marrow transplant survivors. Blood (1999) 1.01
Treatment of extrahepatic portal hypertension in children by mesenteric-to-left portal vein bypass: a new physiological procedure. Eur J Surg (1999) 1.00
G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required. Biol Blood Marrow Transplant (2001) 1.00
Effects of ACE inhibition in normotensive patients with chronic glomerular disease and normal renal function. Kidney Int (1990) 1.00
Synergistic antitumor effects of tumor necrosis factor and gamma-interferon on human colon carcinoma cell lines. Cancer Res (1987) 1.00
Induction of terminal differentiation in human K562 erythroleukemia cells by arabinofuranosylcytosine. J Clin Invest (1984) 0.99
Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin Cancer Res (1997) 0.97
Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant (2009) 0.97
Role of arachidonic acid metabolism in transcriptional induction of tumor necrosis factor gene expression by phorbol ester. Mol Cell Biol (1989) 0.97
The spleen in the Wiskott-Aldrich syndrome: histopathologic abnormalities of the white pulp correlate with the clinical phenotype of the disease. Am J Surg Pathol (1999) 0.96
Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma. J Immunother Emphasis Tumor Immunol (1996) 0.94
Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning. Bone Marrow Transplant (2005) 0.93
Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells. Blood (1984) 0.93
Anaplastic Wilms' tumor: clinical and pathologic studies. J Clin Oncol (1985) 0.92
Management of hepatic epithelioid haemangio-endothelioma in children: what option? Br J Cancer (2004) 0.92
Evaluation of Peru-15, a new live oral vaccine for cholera, in volunteers. J Infect Dis (1997) 0.92
Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. Clin Cancer Res (2000) 0.92
Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro. J Med Chem (1991) 0.92
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol (1996) 0.92
Incorporation of 5-fluorodeoxycytidine and metabolites into nucleic acids of human MCF-7 breast carcinoma cells. Cancer Res (1986) 0.92
Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2001) 0.91
Pharmacosurveillance and quality of care of thalassaemic patients. A large scale epidemiological survey. Eur J Clin Pharmacol (2001) 0.91
Tumor necrosis factor: still a promising agent. J Clin Oncol (1989) 0.91
Effects of 1-beta-D-arabinofuranosylcytosine incorporation on eukaryotic DNA template function. Mol Pharmacol (1984) 0.91
Mechanisms involved in the hyperglycemic response induced by clonidine and other alpha-2 adrenoceptor agonists. J Pharmacol Exp Ther (1984) 0.90
Comparison of alternative buffers for use with a new live oral cholera vaccine, Peru-15, in outpatient volunteers. Infect Immun (1997) 0.90
European biliary atresia registries: summary of a symposium. Eur J Pediatr Surg (2008) 0.90
Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study. Clin Cancer Res (1996) 0.89
Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation. Blood (2000) 0.89
Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens. Bone Marrow Transplant (2008) 0.89
Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. J Cardiovasc Pharmacol (1999) 0.88
Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney Int Suppl (1997) 0.88
Cytokine induction by 41.8 degrees C whole body hyperthermia. Cancer Lett (1995) 0.88
Streptococcus agalactiae (group B) endocarditis--a description of twelve cases and review of the literature. Infection (1987) 0.88
Changing attitudes to the management of ischaemic stroke between 1997 and 2004: a survey of New Zealand physicians. Intern Med J (2006) 0.87
A phase I study of 5-fluorouracil, leucovorin and levamisole. Cancer Chemother Pharmacol (1997) 0.87
Assignment of scores for the hematopoietic cell transplantation comorbidity index: integer vs exact weights. Bone Marrow Transplant (2010) 0.87
High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up. Gynecol Oncol (1997) 0.87
Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer. Clin Cancer Res (1995) 0.86
A phase I study of an oral simulated FOLFOX with high dose capecitabine. Invest New Drugs (2009) 0.86
Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center. Bone Marrow Transplant (2012) 0.86
A concomitant ATP-depleting strategy markedly enhances anticancer agent activity. Apoptosis (2001) 0.86
Comorbidity burden in patients with chronic GVHD. Bone Marrow Transplant (2013) 0.86
Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity. Cancer Res (1989) 0.86
Characterization of the synergistic antiproliferative effects of interferon-gamma and tumor necrosis factor on human colon carcinoma cell lines. J Interferon Res (1990) 0.86